Pierre Fabre SA and Redridge Bio AG have signed an exclusive R&D collaboration and license agreement to identify and develop biparatopic antibody drug candidates against multiple targets, with a focus on precision oncology, dermatology and rare diseases. The agreement provides for participation by Pierre Fabre in Redridge’s series A financing, as well as up-front, milestone and future sales royalty payments.
Aprea Therapeutics Inc. has entered into a material transfer agreement with MD Anderson Cancer Center that will support investigation of APR-1051 as a potential treatment for head and neck squamous cell carcinoma (HNSCC).
The new gene therapy aims to address the root cause of prion disease by using the CHARM epigenetic editing platform from the Whitehead Institute to target and silence the gene that codes for the disease-causing protein.
Medigene AG and Epimab Biotherapeutics Inc. have entered a strategic codevelopment agreement to research and develop off-the-shelf T-cell receptor (TCR)-guided T-cell engagers (TCR-TCEs) for the treatment of immune-related disorders, such as solid tumors.
Bridgene Biosciences Inc. has signed a strategic collaboration and licensing agreement with Takeda Pharmaceutical Co. Ltd. to discover small-molecule drug candidates against targets in immunology and neurology.
Epitopea Ltd. has signed a license and research collaboration agreement with MSD (Merck & Co. Inc.) to identify Cryptigen tumor-specific antigens in an undisclosed solid tumor. Cryptigen TSAs are shared, nonmutated, aberrantly expressed antigens that are derived from what were thought to be noncoding regions of the genome.
Xilio Therapeutics Inc. has announced three wholly owned preclinical programs for masked T-cell engagers targeting prostate-specific membrane antigen (PSMA), claudin 18.2 (CLDN18.2) and six-transmembrane epithelial antigen of prostate 1 (STEAP1).
The Gates Foundation, Novo Nordisk Foundation and Wellcome have announced the launch of the Gram-Negative Antibiotic Discovery Innovator (Gr-ADI), a $50 million investment that will focus on combatting antimicrobial resistance (AMR) caused by a specific range of bacteria that are among the leading contributors to AMR-associated deaths.
RSS
